European Innovation Council

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

AlzeCure Pharma AB is a pharmaceutical company based in Huddinge, Sweden, that specializes in developing drug therapies aimed at treating diseases affecting the central nervous system, with a particular emphasis on Alzheimer's disease. Established in 2012, the company is advancing multiple drug candidates through its research platforms, NeuroRestore and Alzstatin, among others. Current projects include ACD855, which is undergoing Phase I clinical trials for sleep disruptions, traumatic brain injuries, and Alzheimer's disease, along with several other candidates targeting Alzheimer's: ACD856, ACD679, and ACD680. Additionally, AlzeCure is developing ACD857 for eye and ear conditions, and VR1 for neuropathic pain, alongside TrkA-NAM for osteoarthritic pain. Through its focused research initiatives, AlzeCure Pharma aims to address significant unmet medical needs in neurodegenerative diseases.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

Sentante is a medical technology company specialising in the development of robotic teleoperated systems for endovascular procedures. Their core product enables physicians to perform complex surgeries remotely, reducing their exposure to harmful X-rays and expanding telesurgery capabilities.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

PrediSurge is a software company that offers design and support solutions for physicians and medical device companies.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in the development of innovative solutions for microsurgery, focusing on enhancing surgical performance through its motion stabilizer system. This device assists microsurgeons by scaling down motion and filtering out tremors, thereby providing extraordinary control and precision during procedures. The system aims to improve the quality of microsurgical operations, enabling the exploration of new and highly accurate surgical techniques that were previously unavailable. Microsure's technology has been successfully tested in clinical trials, demonstrating its effectiveness in lymphedema surgeries. By facilitating the use of surgeons' own micro-instruments, the device also aims to reduce costs for healthcare facilities while increasing the number of treatment options available for patients.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Senecio Robotics is a technology company focused on combating mosquito-borne diseases through innovative solutions. Drawing expertise from aerospace and defense sectors, the company specializes in developing mosquito-sorting robots that automate the processes of sex sorting and sterilization. Utilizing proprietary technology, which incorporates advanced robotics and machine learning, Senecio Robotics identifies, separates, and sterilizes female mosquitoes. This capability allows customers to implement effective and scalable mosquito control strategies in regions affected by these diseases. The company's name, inspired by the Senecio flower, symbolizes the release of fragile mosquitoes into the environment to promote a healthier future for communities.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Scandinavian Real Heart AB is a medical technology company focused on creating advanced artificial heart solutions. The company's flagship product, the Total Artificial Heart (TAH), aims to closely replicate the natural pumping function, pressure ratios, and pulse of a healthy heart. Designed primarily as a transitional solution, the TAH is intended for patients awaiting heart transplants, offering enhanced functionality compared to existing devices in the market. Through its innovative approach, Scandinavian Real Heart seeks to address the critical needs of individuals facing severe heart conditions and improve their chances of survival while awaiting surgical intervention.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Abbelight is a company specializing in super-resolution microscopy, specifically through its innovative single molecule localization microscopy technology. This technology integrates consumables, hardware, and software to deliver state-of-the-art solutions for biological research, enhancing the ability to observe biological samples with superior resolution. By focusing on simplifying the use of advanced microscopy techniques, Abbelight aims to make these cutting-edge tools accessible to a wide range of laboratories without compromising performance. The company supports scientists throughout their research process, from sample preparation to result analysis, by offering expertise in chemistry, computer science, and optical instrumentation. Abbelight's commitment is to empower researchers in biology, pharmacology, and environmental science with reliable and advanced imaging capabilities.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Inbiome is a trailblazing company in molecular diagnostics, specializing in proprietary molecular culture technology. This innovation enables swift bacterial testing and microbiome analysis, significantly expediting the process compared to traditional methods. The company's primary mission is to advance clinical microbiology by focusing on microbial detection and product development, thereby guiding clinicians towards more accurate and timely diagnoses. By offering advanced molecular technology for microbiome analysis, Inbiome aids in enhancing the understanding of bacteria in the human body, facilitating correct treatments, and mitigating unnecessary complications, costs, and anti-microbial resistance.

GrayMatters Health is a health technology company focused on developing digital therapeutics for mental disorders by enabling volitional regulation of brain processes. The company aims to address mental health and neurological disorders through its innovative solutions, which empower healthcare professionals with neuroscience-based technology. By targeting brain biomarkers associated with these conditions, GrayMatters Health enhances the efficacy, safety, and accessibility of mental healthcare. This approach provides patients with streamlined treatment options, allowing them to manage their disorders more effectively and conveniently.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Syntach is a medical technology company focused on developing innovative cardiac support devices aimed at enhancing the care of individuals suffering from heart failure. The company's flagship product is a permanent, active implant designed to restore the impaired movement of the mitral valve while providing natural support to the heart. This device can be inserted using minimally invasive techniques and is smaller than traditional left ventricular assist devices (LVADs), which contributes to a better quality of life for patients and reduces the risk of complications. Syntach's technology is intended to benefit both men and women who require cardiac support.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

NC Biomatrix is a company focused on developing innovative medical therapies aimed at restoring the natural biomechanics of the spine to alleviate lower back pain. The company specializes in non-invasive treatments, offering an injectable viscous gel that targets the underlying causes of low back pain. By providing a new treatment option for individuals suffering from these common issues, NC Biomatrix aims to improve patient outcomes and enhance quality of life.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Arspectra is a medical technology firm that focuses on unique augmented reality solutions for the healthcare industry.

AkknaTek is a company specializing in the development of patented optical testing technology aimed at improving patient visual outcomes, particularly in the context of intraocular lenses (IOLs). Its flagship product is a lens reviewer designed to assist in the postoperative management of dislocated IOLs, making the treatment process more intuitive and accessible for clinics. By minimizing the risk of unexpected refractive complications following cataract surgery, AkknaTek's technology not only enhances the safety and effectiveness of IOL implants but also reduces the likelihood of the need for additional refractive procedures. The company's innovative approach contributes significantly to better postoperative care for patients undergoing cataract surgery.

Avatar Medical is a developer of a virtual reality medical platform that creates 3D patient avatars to assist surgeons in visualizing medical images. By generating interactive representations based on medical data, the platform enables clinicians to accurately and instantly access critical clinical information. This innovative approach not only enhances the understanding of surgical options but also facilitates the training of medical fellows and improves patient engagement. Avatar Medical aims to transform how medical professionals interact with imaging data, ultimately contributing to better surgical outcomes and patient care.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly in the realm of MRI technology. The company manufactures cylindrical phantoms that streamline the preparation process by eliminating the need for multiple sample vials, facilitating more efficient calibration. Its offerings include a cloud-based data analysis platform that ensures traceability to standardized values, allowing clinicians, medical physicists, and radiographers to obtain consistent quantitative measurements of diseases across different patients, scanners, and clinical environments. By enhancing the precision of MRI imaging, Gold Standard Phantoms aims to improve diagnostic accuracy and potentially reduce healthcare costs.

Gate2Brain is an early-stage biotechnology company dedicated to enhancing drug delivery across biological barriers, with a focus on improving treatments for brain diseases. The company's proprietary technology employs peptide-based innovations to facilitate drug transport across barriers like the blood-brain barrier, aiming to increase treatment efficiency and minimize side effects.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at assisting individuals with neurological impairments, particularly children diagnosed with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company utilizes an innovative approach that enables users to train their brain activity through an engaging and playful interface. By measuring brain waves with an electroencephalogram (EEG) and visualizing the data in a mobile application, children can learn to enhance their concentration and relaxation skills. Brainhero's services also support medical practitioners in early prediction of neurological issues and in adjusting medication dosages for patients experiencing various conditions, including intellectual disabilities, epilepsy, and anxiety.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.

Precisis is a medical device company founded in 2004 and headquartered in Heidelberg, Baden-Württemberg, Germany. The company focuses on developing innovative products aimed at treating epilepsy and enhancing patients' quality of life. Its flagship device provides individualized brain stimulation through a surgical procedure that places the device beneath the scalp, precisely targeting the origin of epileptic activity in the brain. This technology allows for the delivery of therapeutic currents to specific areas, enabling effective treatment without direct contact with brain tissue.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

VIVAN Therapeutics is a company focused on developing personalized cancer therapeutics aimed at revolutionizing cancer care. Utilizing a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, VIVAN offers a comprehensive genomics-based drug screening service that integrates blockchain technology. The company's approach includes the Personal Discovery Process (PDP), which treats each patient as a unique case by engineering their tumor's genetic complexity into a model using fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. This innovative strategy aims to provide less toxic and more affordable treatment options, enhancing the effectiveness of cancer care through tailored recommendations and the development of new diagnostics and decision support tools.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

Cherry Biotech is a biomedical technology company specializing in Organ on Chip systems that facilitate drug discovery and personalized medicine. The company focuses on developing microfluidic technology that allows for the culture and simulation of human organs under various physiological and pathological conditions. Cherry Biotech also provides temperature controllers for rapid temperature adjustments and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately recapitulating the human cellular microenvironment, which is crucial for drug development and toxicity assessment.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. The company specializes in creating antiviral drugs that target the host mechanisms exploited by viruses, thereby providing healthcare institutions with effective treatment options for a variety of pathologies. Through its innovative approach, Meletios Therapeutics aims to fulfill critical medical needs in the realm of antiviral therapeutics.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. The company specializes in creating antiviral drugs that target the host mechanisms exploited by viruses, thereby providing healthcare institutions with effective treatment options for a variety of pathologies. Through its innovative approach, Meletios Therapeutics aims to fulfill critical medical needs in the realm of antiviral therapeutics.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Ostoform Limited is a medical device company based in Dublin, Ireland, specializing in products designed to manage skin complications for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform has developed patented technologies aimed at enhancing ostomy skin health. Its flagship products include a mouldable seal that fits securely around the stoma, preventing corrosive output from contacting the skin, and FLOWASSIST, which directs stoma output away from the skin to minimize irritation and swelling. By addressing these significant challenges faced by ostomy patients, Ostoform aims to improve comfort and overall quality of life, positioning itself as a potential leader in the global ostomy care market.

ATXA Therapeutics Limited is a Dublin-based pharmaceutical company established in 2015 as a spin-out from University College Dublin. The company specializes in developing novel small molecule drugs aimed specifically at treating pulmonary arterial hypertension (PAH), addressing a significant unmet medical need. Founded by Professor Therese Kinsella, ATXA builds on more than 20 years of research, focusing on human prostanoid receptors and their implications in cardiovascular diseases and oncology. The company has received substantial grant funding and has developed a portfolio of highly selective small molecule drugs, validating their effectiveness for various conditions, notably PAH. ATXA's research strategy targets improvements in treatment efficacy by employing human thromboxane receptor antagonists, which enhance vasodilation and mitigate vasoconstriction. The team's expertise spans multiple disciplines, including cardiovascular biology, cancer biology, and drug discovery, positioning ATXA to advance the clinical development of therapies that significantly improve upon existing standards of care for patients with PAH.

ATXA Therapeutics Limited is a Dublin-based pharmaceutical company established in 2015 as a spin-out from University College Dublin. The company specializes in developing novel small molecule drugs aimed specifically at treating pulmonary arterial hypertension (PAH), addressing a significant unmet medical need. Founded by Professor Therese Kinsella, ATXA builds on more than 20 years of research, focusing on human prostanoid receptors and their implications in cardiovascular diseases and oncology. The company has received substantial grant funding and has developed a portfolio of highly selective small molecule drugs, validating their effectiveness for various conditions, notably PAH. ATXA's research strategy targets improvements in treatment efficacy by employing human thromboxane receptor antagonists, which enhance vasodilation and mitigate vasoconstriction. The team's expertise spans multiple disciplines, including cardiovascular biology, cancer biology, and drug discovery, positioning ATXA to advance the clinical development of therapies that significantly improve upon existing standards of care for patients with PAH.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.